BVDV-E2截短基因重组卡介苗对牛的免疫效果评价

为评价牛病毒性腹泻病毒(BVDV)E2截短基因重组卡介苗对牛的免疫效果,将BVDV抗原抗体阴性牛随机分为rBCG-pMV361-E2-1(1 aa-297aa)、rBCG-pMV361-E2-2(1 aa-345 aa)、rBCG-pMV361-E2-3(1 aa-374 aa)、rBCG-pMV361-E2-4(45 aa-297 aa)、rBCG-pMV361-E2-5(45 aa-345 aa)、rBCG-pMV361-E2-6(45 aa-374 aa)、BVDV对照组、BCG对照组和PBS对照组,各组牛免疫相应疫苗后通过特异性抗体检测、淋巴细胞增殖试验、淋巴细胞亚群检测和细胞因子检测分析疫苗的免疫效果。结果显示,BVDV E2截短基因重组卡介苗均可诱导BVDV特异性抗体的产生,rBCG-pMV361-E2-1组抗体水平高于其他重组卡介苗试验组和BVDV对照组。淋巴细胞增殖试验结果显示,rBCG-pMV361-E2-2组SI为2.038±0.21,显著高于其他重组卡介苗试验组(P<0.01)。牛外周血CD4^+、CD8^+T淋巴细胞亚群检测结果显示,rBCG-pMV361-E2-5组牛外周血中CD4^+和CD8^+ T淋巴细胞亚群含量与PBS组比较,差异极显著(P<0.01)。IFN-γ检测结果显示,rBCG-pMV361-E2-1的IFN-γ水平显著高于其他试验组和对照组(P<0.01)。研究表明,rBCG-pMV361-E2-1可诱导接种牛产生较好的体液免疫应答,rBCG-pMV361-E2-1、rBCG-pMV361-E2-2和rBCG-pMV361-E2-5在诱导细胞免疫应答上效果较好。     

Protective immunity of recombinant Mycobacterium bovis BCG expressing rhomboid gene against Eimeria tenella challenge

Two recombinant Mycobacterium bovis BCG (rBCG) strains carrying the Eimeria tenella rhomboid gene (Rho) delivered by extrachromosomal vector pMV261 and integrative vector pMV361 were evaluated for their ability to protect chickens against E. tenella challenge. The chickens were immunized intranasal with BCG, rBCG pMV261-Rho, or rBCG pMV361-Rho twice at a 2-week interval. All the recombinant BCG immunized chickens developed specific immune responses, and there was a significant increases of the percentages of CD4⁺ and CD8⁺ cells compared to the control (P < 0.05). Challenge experiments demonstrated that the two rBCG strains could provide significant protection against E. tenella challenge. But vaccination with rBCG pMV261-Rho induced higher specific antibody titers and produced greater protection rate (56.04%) than rBCG pMV361-Rho group (P < 0.05). These results indicated that M. bovis BCG is a novel vaccine vector to express and present antigens of E. tenella, and rBCG has a potential as vaccine in chickens.     

牛病毒性腹泻-黏膜病病毒Changchun184株E2基因在卡介苗中的表达

在成功克隆牛病毒性腹泻一黏膜病痛毒Changchun184株E2基因的基础上,将E2基因与表达载体pMV261连接,构建了重组穿梭质粒pMV261-E2,后电转化到卡介苗中,获得了具有卡那霉素抗性的重组卡介苗,并对重组卡介苗进行菌落PCR鏊定.在45℃下热诱导E2基因在重组卡介苗中的表达,并对表达产物进行SDS-PAGE电泳和Wesern blotting 分析.结果证明,牛病毒性腹泻-黏膜病病毒Changchun184株E2基因在卡介苗中成功的表达.     

表达牛病毒性腹泻病毒E2蛋白的重组乳酸菌的构建及蛋白免疫原性分析

试验旨在构建能表达牛病毒性腹泻病毒（Bovine viral diarrhea virus，BVDV）E2抗原蛋白的重组乳酸乳球菌（Lactococcus lactis），为进一步研制BVDV乳酸菌口服活载体疫苗奠定基础。将BVDV E2基因克隆后测序，根据乳酸乳球菌的密码子偏嗜性进行优化，再将优化的基因片段插入表达载体pNZ8148中，并电转化乳酸乳球菌NZ9000感受态细胞，构建重组乳酸菌pNZ8148-E2/NZ9000，经1 ng/mL乳链菌肽诱导表达后，对菌体物进行了SDS-PAGE和Western blotting分析。将重组乳酸菌pNZ8148-E2/NZ9000口服免疫6~12月龄健康犊牛，在免疫后不同时间点采集血液样品并分离血清，用间接ELISA方法检测抗体水平。结果显示，PCR扩增到了1 149 bp的目的片段，乳酸菌密码子偏嗜性优化后，GC含量从45.28%变为34.30%。重组质粒pNZ8148-E2经酶切鉴定插入片段与预期大小相符，在菌体裂解物中出现大小约42 ku的条带，与预期蛋白大小一致，且该蛋白可与BVDV E2抗体反应。在免疫犊牛的血清中检测到特异性抗BVDV E2蛋白的抗体。本研究结果表明，表达BVDV E2蛋白的重组乳酸菌口服免疫可诱导犊牛产生特异性的体液免疫反应，该重组菌具有较好的免疫原性。     

表达Ag85基因重组卡介苗的构建

为研发一种更安全、有效的结核病疫苗,用于预防并清除结核病,本试验构建4株分别表达Ag85A、Ag85B、Ag85C、Ag85D基因的重组卡介苗,参考pMV261载体序列和Tuberculist上登录的H37Rv序列设计引物,通过PCR扩增和无缝克隆技术构建含Ag85基因片段的重组pMV261质粒。分别对重组质粒进行PCR、双酶切鉴定后,通过电击转化转染到卡介苗感受态细胞中,利用Kan耐药基因筛选获得重组卡介苗菌株。采用PCR及Western blotting鉴定Ag85A、Ag85B、Ag85C、Ag85D基因在卡介苗中的表达,再对构建成功的重组卡介苗进行培养,用于后续试验。PCR扩增结果表明,构建的重组卡介苗rBCG/Ag85A、rBCG/Ag85B、rBCG/Ag85C和rBCG/Ag85D目的基因片段大小分别为1 447、1 402、1 453和1 330 bp,与预期大小一致,表明目的基因已成功整合到卡介苗中;Western blotting结果表明,Ag85A、Ag85B、Ag85C、Ag85D基因均可在卡介苗细胞内成功表达。本试验利用基因工程技术成功获得4株分别表达Ag85A、Ag85B、Ag85C、Ag85D基因的重组卡介苗,将其分别命名为rBCG/Ag85A、rBCG/Ag85B、rBCG/Ag85C、rBCG/Ag85D。本研究可为进一步将其他抗原基因插入卡介苗细胞构建重组疫苗及疫苗研究提供材料。     

牛病毒性腹泻病毒E0-E2基因融合腺病毒的构建及小鼠免疫效果评价

【目的】 研究牛病毒性腹泻病毒（Bovine viral diarrhea virus,BVDV）E0和E2串联基因重组腺病毒作为基因工程疫苗的应用潜力。【方法】 采用PCR扩增、E0-E2基因融合并构建重组穿梭质粒pDC316-E0-E2,将其与AdMax腺病毒系统的骨架质粒共转染HEK293T细胞包装成重组腺病毒,通过Western blotting进行验证,并通过Reed-Muench法测定病毒滴度,通过肌内、皮下免疫接种小鼠后用ELISA方法及流式细胞检测进行免疫效果试验。【结果】 成功扩增到E0、E2基因目的片段,大小分别为681和1 122 bp,得到了完整的腺病毒Ad5-E0-E2;测定其滴度为1.1×10¹⁰ PFU/mL;Western blotting检测结果显示,Ad5-E0-E2外源基因在HEK293T细胞中表达,得到了与预期相符的目的条带（65 ku）;ELISA检测结果表明,通过肌内和皮下注射Ad5-E0-E2均能产生较高的抗体水平;流式细胞检测显示首免、二免后肌内和皮下注射Ad5-E0-E2组CD4^＋、CD4^＋/CD8^＋比值均极显著高于PBS对照组（P<0.01）。【结论】 本试验成功构建重组腺病毒Ad5-E0-E2,且具有较好的反应原性和免疫原性,能诱导机体产生针对BVDV的特异性抗体。     

应用ＥＬＩＳＰＯＴ试验测定重组卡介苗诱导的Ｔ细胞应答

应用免疫磁性分离技术去除免疫小鼠脾脏细胞中ＣＤ４^ 或ＣＤ8^ Ｔ细胞后，在酶免疫斑点试验中证实表达大肠杆菌ＭalE蛋白的重组卡介苗（rBCG.MalE)诱导的Ｔ细胞应答是ＣＤ４^ t细胞依赖的对MalE、PPD持异Ｔ细胞应答的动态分析结果表明，，rBCG.MalE、ＢＣＧ诱导的特异ＣＤ４^ T细胞应答存在Ｔh1/Th2平衡转换现象，即起始阶段为Ｔh1应答，一段时间后出现Ｔh2应答，并逐步形成Ｔh1/Th２混合应答。这些结果，分为枝杆菌Ｔ细胞应答规律提供了新的认识，同时，亦表明ＢＣＧ是优良的外源抗原表达与运送载体。     

牛病毒性腹泻病毒E0基因重组表达质粒pMG36e-E0的构建与免疫原性分析

利用SacⅠ、HindⅢ限制性内切酶分别对pMG36e与pMD19-T-E0进行双酶切,将目的基因E0整合入穿梭表达载体pMG36e,构建牛病毒性腹泻病毒E0基因重组表达质粒pMG36e-E0。提取重组质粒pMG36e-E0,进行双酶切鉴定及PCR鉴定。将阳性重组质粒pMG36e-E0转化到大肠杆菌DH5α中进行表达,对表达产物进行SDSPAGE和Western-blotting鉴定。用表达的E0蛋白二次免疫家兔,间接ELISA法检测其血清抗体水平。结果,重组质粒经双酶切得到大小分别约为3 600、691bp的2个片段,PCR扩增出691bp的片段,双酶切与PCR鉴定结果表明目的基因E0正确插入到载体pMG36e中。SDS-PAGE电泳结果表明E0基因在大肠杆菌获得了表达,表达产物相对分子质量大小约为27 000。Western-blotting分析结果证明表达产物能被BVDV阳性血清所识别。ELISA检测结果证明表达的E0融合蛋白能刺激动物产生抗体,具有天然蛋白的免疫原性。     

Efficacy of a BVDV subunit vaccine produced in alfalfa transgenic plants

Bovine viral diarrhea virus (BVDV) is considered an important cause of economic loss within bovine herds worldwide. In Argentina, only the use of inactivated vaccines is allowed, however, the efficacy of inactivated BVDV vaccines is variable due to its low immunogenicity. The use of recombinant subunit vaccines has been proposed as an alternative to overcome this difficulty. Different studies on protection against BVDV infection have focused the E2 protein, supporting its putative use in subunit vaccines. Utilization of transgenic plants expressing recombinant antigens for the formulation of experimental vaccines represents an innovative and cost effective alternative to the classical fermentation systems.The aim of this work was to develop transgenic alfalfa plants (Medicago sativa, L.) expressing a truncated version of the structural protein E2 from BVDV fused to a molecule named APCH, that target to antigen presenting cells (APCH-tE2). The concentration of recombinant APCH-tE2 in alfalfa leaves was 1 μg/g at fresh weight and its expression remained stable after vegetative propagation. A methodology based an aqueous two phases system was standardized for concentration and partial purification of APCH-tE2 from alfalfa. Guinea pigs parentally immunized with leaf extracts developed high titers of neutralizing antibodies. In bovine, the APCH-tE2 subunit vaccine was able to induce BVDV-specific neutralizing antibodies. After challenge, bovines inoculated with 3 μg of APCH-tE2 produced in alfalfa transgenic plants showed complete virological protection.     

猪伪狂犬病病毒gD核酸疫苗构建及IL-15基因佐剂对其免疫增强试验

运用PCR技术扩增出伪狂犬病病毒糖蛋白gD基因,将该基因定向克隆于真核表达载体pcDNA3.1+、pCI-neo中,命名重组质粒为pcD-gD、pCI-gD.以小鼠为动物模型,对构建的基因疫苗进行免疫原性的初步评价.为了证明细胞因子是否能增强基因疫苗的免疫效力,本试验用IL-15的表达质粒联合pcD-gD、pCI-gD免疫.结果表明,重组质粒组主要提高细胞免疫水平,特别是联合组中的CD8~+相对其他组别较高.重组质粒在体液免疫方面没有表现出优势,抗体滴度达不到阳性对照组的水平,但是整个抗体水平相对稳定,提示DNA疫苗诱导的抗体维持时间较长.     

Bovine viral diarrhea virus type 1- and type 2-specific bovine T lymphocyte-subset responses following modified-live virus vaccination

Expression of CD25 (interleukin-2 receptor alpha chain) was used to monitor antigen-specific activation of T lymphocyte subsets (CD4+, CD8+, and gamma delta T cells) from cattle immunized with modified-live virus (MLV) bovine viral diarrhea virus (BVDV) vaccines. Two groups of 15 animals each were vaccinated with one dose of either BVDV genotype 1 (BVDV-1) or BVDV-1 and BVDV genotype 2 (BVDV-1/2). Six animals negative for both BVDV antibody and BVDV virus were used as negative controls. Three animals vaccinated 7 and 5 weeks before the start of the experiment with MLV BVDV-1 vaccine served as positive controls. Blood samples were taken from the negative control group, the positive control group, and the BVDV-1/2 group 0, 21, 35, 60, and 90 days after vaccination. Blood samples were taken from the BVDV-1 group 0, 21, and 90 days after vaccination. Isolated peripheral blood lymphocytes from immunized and control animals were incubated for 5 days with and without BVDV-1 or BVDV-2. Compared with nonvaccinated animals, a significant (P <.05) increase in expression of CD25 by CD4+ (60 days), CD8+, and gammadelta T (35 to 90 days) lymphocytes from the group given BVDV-1/2 was detected following in vitro exposure to BVDV-1 or BVDV-2 after vaccination. The CD8+ and gammadelta T cells from the group vaccinated with BVDV-1 had significantly (P <.05) increased expression of CD25 compared with nonvaccinates following postvaccination exposure to in vitro BVDV-1 but not to BVDV-2. There was no significant difference between the two vaccinated groups in CD25 expression on any of the T cell subsets in response to BVDV-1 or BVDV-2 exposure. A single administration of MLV BVDV vaccine may be more effective at stimulating CD8+ and gammadelta T cell-specific immune responses to the homologous genotype than to the heterologous genotype.     

猪瘟兔化弱毒E2基因重组杆状病毒的构建及抗体制备

为制备猪瘟特异性抗体,将猪瘟兔化弱毒E2基因序列修饰后克隆到pFastBac1质粒载体,经转座、转染后构建重组杆状病毒,并用纯化的重组猪瘟E2蛋白免疫大耳白兔制备特异性抗体。实验结果表明成功获得能分泌重组猪瘟E2蛋白的杆状病毒,使用纯化的重组猪瘟E2蛋白制备的猪瘟抗体具有良好的特异性和敏感性,为猪瘟病毒荧光抗体染色液的制备奠定了基础。     

CHO细胞表达牛病毒性腹泻病毒E2蛋白及免疫原性分析

旨在利用悬浮培养CHO细胞表达系统制备牛病毒性腹泻病毒(bovine viral diarrhea virus,BVDV) E2蛋白,并鉴定纯化E2蛋白的免疫原性。本研究以BVDV-1 NADL株基因序列为基础,构建BVDV E2蛋白的重组真核表达质粒pcDNA3.1-BVDV-E2,转染经悬浮培养的CHO细胞进行分泌表达,收集细胞培养上清,进行亲和层析法纯化,SDS-PAGE电泳鉴定蛋白表达和纯化,Western blot鉴定与His抗体和BVDV阳性血清反应性,利用纯化蛋白免疫新西兰大白兔,用细胞间接免疫荧光(IFA)和ELISA鉴定E2蛋白的反应活性。纯化E2蛋白经BCA蛋白定量试剂盒检测后表达量高达1.228 mg·mL^-1;Western blot结果显示,利用His抗体和BVDV阳性血清均可检测到目的蛋白的特异性条带;新西兰大白兔一免后第7天利用间接ELISA可检测到血清抗体阳性,并持续至免疫后第28天,血清抗体效价水平达到1∶1 024 000;IFA试验结果显示,该血清抗体可检测到BVDV感染MDBK细胞中E2蛋白的表达,进一步证实纯化的E2蛋白具有良好的免疫原性和特异性。本研究成功利用CHO悬浮培养真核表达系统制备了纯化的BVDV E2蛋白,该蛋白具有良好的免疫原性,为BVDV的诊断方法及其新型亚单位疫苗研制奠定了基础。     

Evaluation of baits for oral vaccination of European wild boar piglets

The objective of this study was to develop and evaluate new baits for the oral delivery of vaccine preparations to 2–4 month-old wild boar piglets. Baits were prepared using a matrix composed of wild boar feed, wheat flour, paraffin, sacarose and cinnamon-truffle powder attractant with polyethylene capsules dipped into the matrix to introduce vaccine formulation. Physical stability studies demonstrated that baits were stable for at least three days at temperatures as high as 42 °C. Recombinant Escherichia coli expressing the membrane-displayed BM95-MSP1a fusion protein were used to test bacterial viability in the baits and the antibody response in orally immunized wild boar. The E. coli viability was not significantly affected after bait incubation at 25 and 37 °C for 96 h. Bait acceptance studies using artificial feeders in the field showed that baits were accepted by 2–3 month-old animals, the preferred age for vaccination. Orally immunized wild boar piglets excreted recombinant E. coli in the feces and developed antibody titers to recombinant BM95-MSP1a protein, thus confirming that vaccine composition was released and reached the wild boar gastrointestinal track. The results of these experiments support the use of these baits for oral delivery of vaccine formulations to 2–4 month-old wild boar piglets.     

PRRSV GP5蛋白和CSFV E2蛋白在杆状病毒囊膜表面的共展示及展示蛋白的免疫原性分析

本试验旨在构建以杆状病毒表面展示系统为基础的猪繁殖与呼吸综合征和猪瘟双价基因工程亚单位疫苗候选株.利用杆状病毒表面展示技术构建展示猪繁殖与呼吸综合征病毒(PRRSV)GP5蛋白和猪瘟病毒(CSFV)E2蛋白的重组杆状病毒BacSC-Dual-ORF5-E2.该重组病毒带有His6标签,且胞质区域(CTD)和跨膜区域(TM)均来源于杆状病毒囊膜蛋白gp64的CTD和TM.对重组病毒进行western blot分析、激光共聚焦显微镜观察、免疫金电子显微镜检测、动物免疫试验以及淋巴细胞增殖试验.Western blot分析结果表明,重组杆状病毒中表达了重组GP5和E2蛋白;激光共聚焦显微镜检测表明,重组杆状病毒感染昆虫细胞Sf-9后在细胞膜上展示了重组GP5和E2蛋白;免疫金电子显微镜观察表明,重组GP5和E2蛋白展示在杆状病毒囊膜上;动物免疫试验表明,重组杆状病毒免疫小鼠后产生了抗PRRSV和抗CSFV的特异性抗体;淋巴细胞增殖试验表明,重组杆状病毒能诱发较强的细胞免疫应答.本试验成功构建表面展示PRRSV GP5蛋白和CSFV E2蛋白的重组杆状病毒,为下一步应用该重组杆状病毒作为双价亚单位疫苗预防PRRSV和CSFV的混合感染奠定基础.     

共表达牛病毒性腹泻病毒E0基因和牛传染性鼻气管炎病毒gD基因的重组质粒DNA构建及其对小鼠的免疫效应

本研究计划构建能同时表达牛病毒性腹泻病毒(BVDV)和牛传染性鼻气管炎病毒(IBRV)优势抗原基因的重组质粒并研究其免疫效果,旨在为BVD-IBR二联核酸疫苗的研制提供参考.采用PCR扩增目的基因E0及gD并将其依次连接至真核表达载体pVAX1-1RES中,构建pVAXl-E0-IRES-gD重组真核表达载体;将pVA...     

The live attenuated bovine viral diarrhea virus components of a multi-valent vaccine confer protection against fetal infection

Fetal infection with bovine virus diarrhea virus (BVDV) causes severe economic loss and virus spread in cattle. This study investigated the ability of modified live BVDV I and II components of a commercially available modified live virus (MLV) vaccine (Breed-Back FP 10, Boehringer Ingelheim Vetmedica Inc.) to prevent fetal infection and abortion, and therefore the birth of persistently infected animals. Heifers immunized with vaccine 4-8 weeks before insemination showed no adverse effects. All vaccinated animals had seroconverted to BVDV 4 weeks after immunization. Pregnant heifers were divided into two vaccination and two control groups and challenged with type I or II BVDV on days 60-90 of gestation. Seroconversion, clinical signs, immunosuppression, viremia, mortality, abortion rate, and fetal infection were studied. Post-challenge, 6/11 (type I challenged) and 8/11 (type II challenged) vaccinated heifers were free from clinical signs of BVD. Post-challenge clinical signs noted in the vaccinated groups were mild to moderate, while all unvaccinated controls had clinical signs ranging from moderate to severe. Viremia was not detected post-challenge in any of the vaccinated heifers. However, 100% of the controls were BVDV viremic on at least 1 day post-challenge. One of 22 vaccinated heifers had transient leukopenia, whereas 2/8 and 6/7 unvaccinated heifers in control groups I and II, respectively, had transient leukopenia. Type II BVDV infection led to abortion or death in 86% of unvaccinated heifers. The corresponding vaccinated group showed no deaths or abortions. All control group fetuses were infected with BVDV. The test vaccine gave 91% (type I BVDV challenged) and 100% (type II BVDV challenged) protection from fetal infection. This vaccine is safe and effective against fetal infection, abortion (type II BVDV) and the birth of persistently infected animals.     

Efficacy of an inactivated recombinant vaccine encoding a fimbrial protein of Pasteurella multocida B:2 against hemorrhagic septicemia in goats

This study was carried out to determine the antibody responses and protective capacity of an inactivated recombinant vaccine expressing the fimbrial protein of Pasteurella multocida B:2 following intranasal vaccination against hemorrhagic septicemia in goats. Goats were vaccinated intranasal with 10⁶ CFU/mL of the recombinant vaccine (vaccinated group) and 10⁶ CFU/mL of pET32/LIC vector without fimbrial protein (control group). All three groups were kept separated before all goats in the three groups were challenged with 10⁹ CFU/mL of live pathogenic P. multocida B:2. During the course of study, both serum and lung lavage fluid were collected to evaluate the antibody levels via enzyme-linked immunosorbent assay. It was found that goats immunized with the inactivated recombinant vaccine developed a strong and significantly (p < 0.05) higher specific IgA and IgG responses in both serum and lung lavage fluid samples compared to the control and unvaccinated groups. Following intratracheal challenge, the rate of isolation was 17% for the vaccinated group, 67% for the control group and 100% for the unvaccinated group. However, none of the goat from the vaccinated group had P. multocida B:2 in the liver, tonsil and heart. Therefore, the study revealed that an inactivated recombinant vaccine significantly provides significant protection against high dose challenge and enhances the stimulation of the local and systemic immunities.     

中国流行株ＨＩＶ—1gag—gp120与ＩＬ／ＩＬ—６共表达核酸疫苗质粒的构建和

以pcDNA3.１( ）为载体，构建了中国流行株ＨＩＶ－1gag-gp1２０嵌合基因的核酸疫苗质粒；并以pIRES1neo为载体，构建了gap-gp120与ＩＬ－２／ＩＬ－６共表达的２种核酸疫苗质粒。将核酸疫苗质粒在体外转染ＢＨＫ－２１细胞，ＥＬＩＳＡ方法检测到３种核酸疫苗质粒均表达了目的ＨＩＶ－１结构蛋白。将核酸疫苗质粒免疫小鼠，免疫学指标检测结果表明，在本实验条件下，未能检测到含有gap-gp120的核酸疫苗质粒免疫鼠的细胞免疫和体液免疫功能的明显改变；而与ＩＬ－２／ＩＬ６共表达的２种核酸疫苗质粒使免疫鼠ＣＤ^ 4、ＣＤ^ 8T细胞数量明显升高，ＣonA和ＬＰＳ诱导的细胞增殖能力显著增强，ＣＴＬ活性明显提高，表明ＩＬ－２和ＩＬ－６有效地发挥了免疫佐剂作用。     

牛病毒性腹泻病毒E2基因在毕赤酵母GS115中的表达与鉴定

将牛病毒性腹泻病毒(Bovine viral diarrhoea-mucosal disease virus,BVDV)河北分离株HB-bd毒株E2基因去除跨膜区获得sE2基因,将sE2基因克隆入巴斯德毕赤酵母(P.pastoris)分泌型表达载体pPIC9K中,筛选培养后提取阳性重组质粒,经酶切和PCR鉴定,命名为pPIC9K-sE2。重组质粒pPIC9K-sE2经SalⅠ酶切后,电穿孔导入P.pastorisGS115基因进行整合,使外源基因sE2稳定地整合到P.pastoris染色体中,G418筛选得到阳性高拷贝转化子GS115-pPIC9K-sE2。经甲醇诱导表达后,sE2融合蛋白获得了表达,表达产物经SDS-PAGE、Western-blot和Dot-ELISA分析,确定其表达的sE2融合蛋白相对分子质量大小为37 000,且具有天然蛋白的抗原特异性。免疫活性研究证明,P.pastoris表达的sE2蛋白能刺激动物产生抗体。